Masana'antu kai tsaye suna ba da 4-Dibuthylamino-2-Hydroxybenzophenone-2-Carboxylic Acid (BBA) CAS 54574-82-2

Yawancin lokaci muna tunani kuma muna yin daidai da canjin yanayin ku, kuma mu girma.Mu burin a cimma wani arziki hankali da jiki da mai rai ga Factory Kai tsaye wadata 4-Dibuthylamino-2-Hydroxybenzophenone-2-Carboxylic Acid (BBA) CAS 54574-82-2, Our nufin zai zama don taimaka abokan ciniki san su aims. .Mun kasance muna samar da kyawawan yunƙuri don cimma wannan matsala ta nasara kuma muna maraba da ku da gaske don yin rajistar mu.
Yawancin lokaci muna tunani kuma muna yin daidai da canjin yanayin ku, kuma mu girma.Muna burin samun nasara mai wadatar hankali da jiki tare da masu rai donChina 4-Dibuthylamino-2-Hydroxybenzophenone da Bba, Our ci gaba da samuwa na high sa kayayyakin da mafita a hade tare da mu m pre-sayar da sabis na bayan-tallace-tallace tabbatar da karfi gasa a cikin wani ƙara duniya kasuwar.maraba da sababbin abokan ciniki da tsoffin abokan ciniki daga kowane fanni na rayuwa don tuntuɓar mu don dangantakar kasuwanci ta gaba da nasarar juna!

2'-Methoxy-3'-nitro-biphenyl-3-carboxylic acid ana amfani dashi azaman matsakaici na Eltrombopag.
Eltrombopag, wanda GlaxoSmithKline (GSK) ya haɓaka a Burtaniya kuma daga baya aka haɓaka tare da Novartis a Switzerland, shine farkon kuma kawai wanda aka amince da ƙananan ƙwayoyin cuta marasa peptide TPO agonist a duniya.An amince da Eltrombopag ta FDA ta Amurka a cikin 2008 don maganin cututtukan thrombocytopenic purpura (ITP), kuma a cikin 2014 don maganin anemia mai tsanani (AA).Hakanan shine magani na farko da FDA ta Amurka ta amince don maganin AA a cikin shekaru 30 na baya-bayan nan.
A cikin Disamba 2012, FDA ta Amurka ta amince da Eltrombopag don maganin thrombocytopenia a cikin marasa lafiya tare da ciwon hanta na kullum C (CHC), don haka marasa lafiya na hepatitis C tare da rashin jin dadi saboda ƙananan platelet zasu iya farawa da kuma kula da interferon bisa daidaitattun maganin cututtuka na hanta.A ranar 3 ga Fabrairu, 2014, GlaxoSmithKline ya sanar da cewa FDA ta ba da nasarar cancantar maganin miyagun ƙwayoyi na Eltrombopag don maganin hemopenia a cikin marasa lafiya tare da anemia mai tsanani na sinadarai (SAA) waɗanda ba su da cikakkiyar amsa ga immunotherapy.A ranar 24 ga Agusta, 2015, FDA ta Amurka ta amince da Eltrombopag don maganin thrombocytopenia a cikin manya da yara masu shekaru 1 da haihuwa tare da thrombocytopenia na rigakafi na yau da kullum (ITP) waɗanda basu da isasshen amsa ga corticosteroids, immunoglobulins ko splenectomy.A ranar 4 ga Janairu, 2018, an amince da Eltrombopag da za a jera shi a kasar Sin don maganin thrombocytopenia na rigakafi na farko (ITP).

Yawancin lokaci muna tunani kuma muna yin daidai da canjin yanayin ku, kuma mu girma.Mu burin a cimma wani arziki hankali da jiki da mai rai ga Factory Kai tsaye wadata 4-Dibuthylamino-2-Hydroxybenzophenone-2-Carboxylic Acid (BBA) CAS 54574-82-2, Our nufin zai zama don taimaka abokan ciniki san su aims. .Mun kasance muna samar da kyawawan yunƙuri don cimma wannan matsala ta nasara kuma muna maraba da ku da gaske don yin rajistar mu.
Factory Kai tsaye wadataChina 4-Dibuthylamino-2-Hydroxybenzophenone da Bba, Our ci gaba da samuwa na high sa kayayyakin da mafita a hade tare da mu m pre-sayar da sabis na bayan-tallace-tallace tabbatar da karfi gasa a cikin wani ƙara duniya kasuwar.maraba da sababbin abokan ciniki da tsoffin abokan ciniki daga kowane fanni na rayuwa don tuntuɓar mu don dangantakar kasuwanci ta gaba da nasarar juna!